M&A / Deals Alzecure enters collaboration and with Lilly for Alzheimer’s project PharmaTimesPartnership grants Lilly global rights to Alzstatin ACD680NeuroscienceRead full story pharminent June 9, 2026 (Last updated: June 9, 2026) PharmaTimes Partnership grants Lilly global rights to Alzstatin ACD680 Neuroscience Read full story Post navigation Previous: ADA: AstraZeneca hands Structure a win with ‘relatively underwhelming’ GLP-1 pill dataNext: Cancer biotech Parabilis books record IPO, raising $670m Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026